Answer:
The Ebola epidemic is still ravaging West Africa, and the death toll has passed 10,000. The labor force and human capital of the economies of the countries affected by Ebola are declining with the increasing number of deaths and people infected with Ebola. The reduction in labor resources caused by the many deaths and the underutilization of human capital caused by the large number of sick people is leading to a decline in output
I have invented an antiviral drug that will cure this deadly disease. The drug is made from a batch of antiviral culture along with minute concentrations of potassium chloride. To produce this drug on large scale, we will need certain capital—sodium chloride, lab equipment, syringes, and oxygen devices to help with breathing. Moreover, we will also need labor in large numbers to act as support and nursing staff who will distribute and administer the drug. The capital needed for this drug is currently used for producing and distributing an antiviral drug for influenza. Considering the urgent need we are facing, I believe that the antiviral drug for the deadly disease Ebola is the need of the hour, and the firm therefore should transfer its resources from producing the flu drug to producing the Ebola antiviral drug. The firm will face a trade-off here, which will lead to a decrease in the production of the flu drug. However, this new drug will certainly improve the condition of those affected by Ebola.
Within a few years, I am sure that the countries that suffered the epidemic will recover their labor. We can soon expect an increase in their production possibilities and a right shift in their PPCs.
Explanation:
